These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17229332)

  • 1. Systemic immunoglobulin light-chain amyloidosis.
    Comenzo RL
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing systemic light-chain amyloidosis.
    Comenzo RL
    J Natl Compr Canc Netw; 2007 Feb; 5(2):179-87. PubMed ID: 17335687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
    Charliński G; Jurczyszyn A; Wiktor-Jedrzejczak W
    Przegl Lek; 2014; 71(2):102-9. PubMed ID: 25016786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light chain (AL) amyloidosis: update on diagnosis and management.
    Rosenzweig M; Landau H
    J Hematol Oncol; 2011 Nov; 4():47. PubMed ID: 22100031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amyloid light chain amyloidosis].
    Suzuki K; Shimizu T
    Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
    Gertz MA
    Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin light chain amyloidosis.
    Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
    Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
    Picken MM
    Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Light-chain amyloidosis: SCT, novel agents and beyond.
    Rosenzweig M; Giralt S; Landau H
    Bone Marrow Transplant; 2013 Aug; 48(8):1022-7. PubMed ID: 23103675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
    Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
    Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights and modern treatment of AL amyloidosis.
    Chaulagain CP; Comenzo RL
    Curr Hematol Malig Rep; 2013 Dec; 8(4):291-8. PubMed ID: 24026941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.